To date, five distinct but homologous gene sequences coding for muscarinic receptors (m1, m2, m3, m4, m5) have been identified and cloned. [1] [2] [3] [4] [5] Pharmacologically, four subtypes (M 1 , M 2 , M 3 , M 4 ) have been defined. [6] [7] [8] Among these muscarinic receptor subtypes, M 3 receptors are localized in smooth muscle and mucosal glands and mediate contraction and mucus secretion. M 1 receptors, localized to the post-ganglionic cholinergic nerve terminals and glands, facilitate neurotransmission and gastric secretion. Neuronal M 2 receptors provide a functional negative feedback modulation of acetylcholine (ACh) release.
however, few structure classes with sufficient M 3 selectivity have been discovered to date. 14) As a part of our program for developing a muscarinic M 3 receptor antagonist for the treatment of pulmonary or urinary diseases, we pursued M 3 antagonists that are structurally distinct from a series of 2-(4,4-difluorocyclopentyl)-2-phenylacetamide derivatives such as Compound A 13) and have selectivity for M 3 receptors two orders of magnitude greater than those for M 1 and M 2 receptors. As a result of screening of our in-house chemical collection, a thiazole-4-carboxamide derivative (1) was identified as a new lead structure. Avoiding the structural complexity of 1 due to the five chiral centers, we first replaced the perhydronaphtylmethyl moiety with a naphtylmethyl group, without regard for the binding affinity of the compound. Optimization of the compound (2) by using a solution-phase parallel synthesis method led us to the identification of M 3 selective antagonists (3e, f) showing high potency (K i ϭca. 1 nM) for M 3 receptors and greater than 100-fold selectivity for M 3 over M 1 and M 2 receptors.
In this paper, we describe the synthesis of aminothiazole derivatives, their binding affinities for M 1 -M 3 receptors in the binding assay, and their selectivity for M 3 over M 1 and M 2 receptors, and discuss their structure-activity and structure-selectivity relationships.
Chemistry
Preparation of 3f was outlined in Chart 1 as a representative procedure for the series of 2-aminothiazole-4-carboxamide derivatives. The 2-aminothiazole-4-carboxylic acid (5) was derived from a thiourea (4) and ethyl 2-bromopyruvate by a conventional method in 86% yield. The (3S)-3-aminomethylpiperidine (10), a component of 3f, was prepared from a racemic ethyl nipecotate (7) . 15) Optical resolution of ethyl nipecotate was performed using a standard method using L-tartaric acid to give a (3R)-ethyl nipecotate (8) . Following the reduction of 8 with LAH, the piperidine nitrogen was protected as a tert-butylcarbamate to afford the alcohol, which was converted to an azide (9) via the mesylate in 69% yield from 8. 9 was hydrogenated to produce the amine (10) in quantitative yield. Coupling of the acid (5) with 10 was achieved using a standard protocol (EDCI and HOBT) to give an amide (6) . Deprotection of the Boc group in 6 under acidic conditions, followed by reductive alkylation by treatment with an aldehyde (13) 16) in the presence of NaBH(OAc) 3 afforded 3f in 76% yield.
Results and Discussion
Compounds prepared by a solution-phase parallel synthesis were tested in an initial screen to assess the percentage of inhibition at 1 mM in the binding assay for the muscarinic M 3 receptor subtype in transfected CHO cells. 17) Selected compounds showing greater than 50% inhibition at 1 mM were subsequently purified or re-synthesized and tested in the binding assay for muscarinic receptor subtypes (M 1 , M 2 , M 3 ) to determine the K i values 18) and subtype selectivity (M 1 /M 3 , M 2 /M 3 ).
Before applying the solution-phase parallel synthesis for optimization of 2, we prepared the three compounds (14-16) and tested their binding affinity to examine the necessity of the asymmetric carbon on the piperidine ring of 2. Of them, compound (14) bearing a (3S)-piperidine moiety clearly showed the best binding and selectivity profiles (Table 1) .
Thus, the (3S)-piperidine part being fixed, we tried to replace the 1,4-benzodioxane moiety of 14 with various functional groups using parallel synthesis ( Table 2) . Among 26 kinds of substituents introduced into the 2 position (R 1 ) on the aminothiazole ring, only an N-methylphenylamino group (14a) showed inhibitory activity comparable to 14. The K i values of 14a for the M 1 , M 2 and M 3 receptor subtypes were confirmed to be 1200, 54000 and 230 nM, respectively, and the selectivity for M 3 over the M 1 and M 2 receptors was 5-and 230-fold, respectively.
Comparison of these binding data with those of 14 indicated that an N-methylphenylamino group played an important role in improving the selectivity for M 3 over M 2 receptors, while this moiety did not contribute to enhancement of the M 3 binding affinity. Thus, we selected an N-methyl-Nphenylamino group as the optimized R 1 segment. Next, we tried to optimize the naphtylmethyl moiety of 14a, which was tentatively introduced into the piperidine nitrogen to avoid the complexity of the stereocenters of the perhydronaphthyl group in 1, by substituting this moiety with various aromatic or cycloalkyl groups (Table 3) . In this case, compounds were screened by the percentage of inhibition for M 3 receptors at 0.1 mM. Two substituents, a cyclohexylethyl and a cyclooctylmethyl group, seemed to be most effective in enhancing the binding affinity among 23 kinds of functional groups. Evaluation of the K i values of the two compounds (3a, b) for the three receptor subtypes indicated that 3b with a cyclooctylmethyl moiety displayed more potent activity (K i ϭ20 nM) for M 3 receptors than 3a. Also, 3b had better selectivity for M 3 over M 2 receptors (M 2 /M 3 ϭ74). Therefore, further optimization of the R 2 segment in 3b was conducted by replacing the cyclooctylmethyl moiety with larger ringsized cycloalkylmethyl groups such as a cyclononyl-and cyclodecylmethyl groups (Table 4) .
Replacement with a cyclononylmethyl group (3c) resulted in enhancement of the M 3 binding affinity to some extent, while the selectivity for M 3 over M 1 and M 2 receptors was maintained. Introduction of a cyclodecylmethyl group (3d) dramatically improved the binding affinity and selectivity for M 3 over M 2 receptors. In the process of identification of the 2-cyclopentyl-2-phenylacetamide derivatives, 17) we found that installment of a double bond into the piperidinyl side chain was effective in enhancing M 3 binding affinity. Therefore, we prepared cycloalkenylmethyl derivatives (3e, f) 438 Vol. 53, No. 4 % inhibition at 0.1 mM and evaluated their binding affinities. As expected, the cyclooctenylmethyl derivative (3e) displayed more potent binding activity and much better selectivity for M 3 over M 1 and M 2 receptors than the corresponding cyclooctylmethyl derivative (3b). Similarly, the cyclononenylmethyl derivative (3f) was 10-fold more active and approximately 3-fold more selective for M 3 over M 2 receptors than the cyclononylmethyl derivative (3c). Further derivatization of 3f was performed for the optimization of the R 3 segment (Table 5 ). These derivatizations indicated that the distance between the amide carbonyl and cationic amine parts, and a suitable structural rigidity as the R 3 segment were important for the M 3 binding affinity. Based on these modifications, the (3S)-3-aminomethylpiperidine moiety was an optimal R 3 segment. It is interesting to note that although both 3f and Compound B (Fig. 1) 14) have excellent M 3 potency and selectivity for M 3 over M 1 and M 2 receptors, each of them has a different stereochemical structure in terms of the 3-aminomethylpiperidine portion. One of the reasons we assume is that the spatial arragangement of the whole molecule plays a key role in the binding interaction between the M 3 receptors and the antagonists. On the other hand, Compound A ( Fig. 1) with a conservative structure had a good potency for M 3 recptors, but was only selective for M 3 over M 2 receptors. Comparison of the structure of Compound A with those of the M 3 selective antagonists (3f and Compound B) suggests that a larger size of the acid part or the cationic amine side chain would contribute to the enchnced selectivity for M 3 over M 1 receptors.
In conclusion, we have succeeded in identifying a new class of M 3 selective antagonists by derivatization of the lead compound (1) through the combinatorial approach. In this class, the cyclooctenylmethyl (3e) and cyclononenylmethyl (3f) derivatives were found to show potent binding affinities for M 3 receptors, together with greater than 100-fold selectivity for M 3 over M 1 and M 2 receptors. These aminothiazole derivatives are the alternative examples showing greater than 100-fold selectivity for M 3 over M 1 and M 2 receptors, 14) and these might be useful tools for complete characterization of the roles of M 3 receptor subtype and better understanding for the binding mode of the M 3 selective antagonist.
Experimental
Materials and Methods All reagents and solvents were of commercial quality and used without further purification unless otherwise noted. Melting points were determined with a Yanaco MP micromelting point apparatus and were not corrected.
1 H-NMR spectra were obtained on a JEOL AL400 with tetramethylsilane as an internal standard. Mass spectrometry was performed with a JEOL JMS-SX 102A. Elemental analysis was performed on an EA-1108 FISONS Instruments CHNOS analyzer. TLC was done using Merck Kieselgel F 254 pre-coated plates. Silica gel column chromatography was carried out on Wako gel C-200.
2-(N-Methyl-N-phenylamino)thiazole-4-carboxylic Acid (5) 1) To a solution of 4 (3.0 g, 20 mmol) in EtOH (70 ml) was added ethyl bromopyruvate (3.0 ml, 1.24 mmol), and the mixture was heated at 90°C for 3 h. After cooling to room temperature, the solvent was removed under reduced pressure, and the residue was diluted with EtOAc. The organic layer was washed with aqueous NaHCO 3 solution and brine, dried over MgSO 4 , and evaporated. The suspension of the residue in toluene-hexane was heated, and the insoluble material was removed by filtration. The filtrate was concentrated under reduced pressure, and the resulting crystalline solid was collected by filtration, washed with toluene and dried to produce ethyl 2-(N-phenylamino)thiazole-4-carboxylate (3.4 g, 14 mmol, 70%).
2) To a solution of ethyl 2-(N-phenylamino)thiazole-4-carboxylate (2.5 g, 10 mmol) in DMF (25 ml) was added NaH (60% in mineral oil, 600 mg, 15 mmol) at 0°C. After the mixture was stirred for 15 min at 0°C, MeI (3.1 ml, 50 mmol) was added and the mixture was stirred for 2 h. The reaction was quenched by adding aqueous NH 4 Cl solution, and the mixture was extracted with Et 2 O. The organic phase was dried (MgSO 4 ), and evaporated. The residue was purified by silica gel column chromatography (hexaneEtOAc, 10 : 1 elution) to give ethyl 2-(N-methyl-N-phenylamino)thiazole-4-carboxylate (2.2 g, 2.4 mmol, 84%) as a colorless oil.
3) To a solution of ethyl 2-(N-methyl-N-phenylamino)thiazole-4-carboxylate (1.9 g, 7.2 mmol) in MeOH (40 ml) was added 3 N NaOH (15 ml), and the mixture was stirred for 15 h at room temperature. After completion of the reaction, the mixture was washed with Et 2 O. The aqueous phase was acidified with 3 N HCl, and extracted with CHCl 3 . The organic phase was dried (MgSO 4 ), and evaporated to give 5 (1. 2) A mixture of 6 (1.04 g) in 10% HCl-MeOH (10 ml) was stirred at room temperature for 13 h. The reaction mixture was basified (pH 9) with aqueous NaHCO 3 27 (1H, m), 1.40-1.53 (1H, m), 1.65-1.81 (3H, m), 1.83-1.91 (1H, m) 
3) To a solution of N-[(3S)-piperidin-3-ylmethyl]-2-(N-methyl-N-phenyl-
amino)thiazole-4-carboxamide (25 mg, 0.076 mmol) in THF (1 ml) was added 13 (30 mg, 0.20 mmol), AcOH (6 mg, 0.10 mmol), and NaBH(OAc) 3 (50 mg, 0.23 mmol), and the mixture was stirred at room temperature for 16 h. The reaction was quenched by adding saturated aqueous NaHCO 3 solution and extracted with CHCl 3 . The organic phase was dried (Na 2 SO 4 ), and evaporated. The residue was purified by preparative TLC (CHCl 3 -MeOHϭ9 : 1) to give 3f (27 mg, 0.058 mmol, 76%) as a colorless oil: 
